Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Sandoz unveils "Bio100" strategy and sets clear financial targets, shares rise

Sandoz shares rose 4.4% to CHF 71.22 after the company unveiled its long-term “Bio100” initiative, aiming to expand its biosimilar portfolio from 13 to more than 100 products by 2040 and to increase market coverage to around 80% by 2035. For 2025–2030 Sandoz targets annual net sales growth in the mid- to high-single-digit range and an adjusted EBITDA margin of 25–27% by 2030; by 2035 it aims to double net sales and achieve a margin above 30%. To support the strategy, Sandoz announced an investment in a new biosimilar active pharmaceutical ingredient manufacturing site in Ljubljana, Slovenia. Analysts had already issued positive assessments with price targets of CHF 75–80, helping push the stock toward its 52-week high. » Mere på de.investing.com
Sandoz aims to more than double revenue by 2035 through biosimilar push

Sandoz plans to more than double revenue by 2035 by expanding its biosimilar portfolio and targets a core EBITDA margin of over 30% (excluding GLP-1 effects). By 2040 the portfolio should grow to more than 100 biosimilars (currently 13) and market coverage for expiring patents should rise to around 80% by 2035. For 2025–2030 the company expects average annual net sales growth in the mid- to high-single-digit range at constant exchange rates and a core EBITDA margin of 25–27% (including GLP-1). Sandoz also confirmed its existing mid-term outlook through 2028; net sales for 2025 were $11.1 billion. » Mere på de.investing.com
Sandoz: one-year investment yields around 50% return

If 100 CHF had been invested in Sandoz a year ago (closing price 48.91 CHF), the investor would now hold 2.045 shares worth 150.07 CHF at a price of 73.40 CHF on 18.08.2026. That corresponds to a value increase of 50.07 percent. The Sandoz share was first listed on 04.10.2023 at a price of 24.00 CHF; stock splits and dividends are not included in the calculation. » Mere på finanzen.net

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2026 har Sandoz allerede udloddet 0,87 € i udbytte. Den seneste udlodning fandt sted i april.

Virksomhedstal

I det seneste kvartal havde Sandoz en omsætning på 4,94 mia. € og et nettoresultat på 93,42 mio. €

(EUR)	juni 2026	YoY
Omsætning	4,94 mia.	-
Bruttofortjeneste	2,3 mia.	-
Nettoresultat	93,42 mio.	-
EBITDA	959,02 mio.	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	30,45 mia. €
Antal aktier	432,01 mio.
Højeste/laveste i 52 uger	71,75 € - 24,82 €
Udbytteafkast	1,23 %
Udbytte TTM	0,87 €
Beta	0,49
P/E (PE Ratio)	54,16
PEG (PEG Ratio)	0,28
K/I (PB Ratio)	3,94
P/S (PS Ratio)	3,07

Virksomhedsprofil

Die Sandoz Group AG entwickelt, produziert und vermarktet weltweit generische Arzneimittel und Biosimilars. Sie entwickelt, produziert und vermarktet fertige Darreichungsformen von Arzneimitteln mit kleinen Molekülen für Dritte. Darüber hinaus bietet das Unternehmen Produkte auf Protein- oder anderer Biotechnologiebasis, einschließlich Biosimilars, sowie biotechnologische Produktionsdienstleistungen und Antiinfektiva, wie pharmazeutische Wirkstoffe und Zwischenprodukte, vor allem Antibiotika, an. Das Unternehmen wurde 1886 gegründet und hat seinen Hauptsitz in Rotkreuz, Schweiz.